NMS will be participating and/or presenting data at the following events.
Posters available upon request at the following address:
Questo indirizzo email è protetto dagli spambots. E' necessario abilitare JavaScript per vederlo.
2013
- April 6-10
AACR 2013
Washington, USA
Web link
Abstract 2091
Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models
Authors: Ardini E, Banfi P, Quartieri F, Polucci P, Avanzi N, Ballinari D, Mancini L, Felder E, Donati D, Galvani A, Pesenti E, Isacchi A, Menichincheri M
Abstract 2092
The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models
Authors: Ardini E, Menichincheri M, Banfi P, Casero D, Giorgini ML, MB Saccardo, Amboldi N, Avanzi N, Donati D, Isacchi A, Pesenti E, Galvani A
Abstract 2097
Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase
Authors: Colombo R, Caldarelli M, Giorgini ML, De Grassi A, Ciomei M, Pezzetta D, Ballinari D, Montagnoli A, Pesenti E, Donati D, Galvani A
Abstract 3259
Novel isoquinolinone derivatives with dual PARP-1/PARP-3 inhibitory activity are highly active against pTEN mutated colorectal cancer and glioblastoma models
Authors: Montagnoli A, Rainoldi S, Mazzoleni S, Ciavolella A, Lupi R, Casale E, Ciomei M, Pesenti E, Donati D, Galvani A, Papeo G
Archive 2012
- November 6-9
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Dublino, Ireland
Web link
Abstract 231
A novel siRNA screening approach for target identification in oncology: focus on purinome enzymes
Authors: F. Gasparri, LM. Gianellini, ML. Giorgini, A. Carugo, L. Raddrizzani, C. Perrera, R. Lupi, A. Isacchi, A. Galvani, R. Colombo
Abstract 309
Characterization of a novel, highly potent and selective RET inhibitor with antitumor efficacy in RET dependent models
Authors: E. Ardini, N. Amboldi, N. Avanzi, P. Banfi, C. Cristiani, D. Donati, A. Galvani, A. Isacchi, E. Pesenti, M. Menichincheri
Abstract 517
NMS-P153, a tight-binder inhibitor of the spindle assembly checkpoint kinase MPS1
Authors: R. Colombo, M. Caldarelli, ML, Giorgini, O. Milani, N. Avanzi, F. Sola, E. Pesenti, D. Donati, A. Galvani
Abstract 544
Characterization of potent and well tolerated second generation FLT3 Inhibitors
Authors: M. Ciomei, N. Amboldi, S. Cribioli, D. Donati, I. Fraietta, A. Galvani, C. Nuccio, E. Pesenti, G. Texido Romero, A. Lombardi Borgia - October 27-29
XIV Congresso Nazionale di Oncologia Medica
Roma, Italy
Web link - September 2-6
EFMC-ISMC 2012, 22nd International Symposium on Medicinal Chemistry
Berlin, Germany
Web link - July 17-20
XXII National Meeting on Medicinal Chemistry
Palermo, Italy
Web link
Oral presentation
The discovery, synthesis and SAR studies of a new class of potent and selective PARP-1 inhibitors as anticancer agents
GL. Papeo - June 27-29
XI National Biotechnology Congress
Varese, Italy
Web link
Oral presentation
An integrated approach for the development of anticancer drugs
A. Isacchi - June 14-16
Molecular basis for resistance to target agents
Trento, Italy
Web link - June 10-12
12th Annual drug discovery leaders summit
Zurigo, Switzerland
Web link - May 30-31
Drug Discovery Automation
Hamburg, Germany
Web link - May 2-4
Ninth Annual Meeting of the Bioinformatics Italian Society
Catania, Italy
Web link
Abstract
A comprehensive dataset including 16 loci based DNA fingerprinting of a broad tumour cell line panel for cancer research
A. Somaschini, E. Scacheri, A. Nuzzo, N. Amboldi, D. Ballinari, G. Ukmar, A. Isacchi, R. Bosotti
Abstract
An interactive tool enabling a comparative analysis of STR profiles
G.Ukmar, R. Bosotti, A. Somaschini, J. Malysko, L. Raddrizzani, G. Masetti, A. Milani, E. Scacheri, A. Isacchi, A. Nuzzo - April 19-20
Terzo congresso annuale organizzato dall'Italian Chapter dell'ISMRM, Napoli
Napoli, Italy
Web link
Oral presentation
MRI evaluation of dendritic cell vaccination protocol in a murine model of breast cancer (MMTV-hRas)
M. Russo, A. Degrassi - April 15-17
6° Meeting di Nuove Prospettive in Chimica Farmaceutica
Riccione, Italy
Web link
Oral presentation
NMS-P715: different sinthetic approaches toward the synthesis of a potent and selective MPS1 Kinase inhibitor
H. Posteri - March 31-April 4
AACR 2012
Chicago, IL
Web link
Oral presentation Abstract 2940
Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death
P. Magnaghi, R. D'Alessio, B. Valsasina, N.R. Avanzi, S. Rizzi, D. Asa, F.Gasparri, L. Cozzi, U. Cucchi, C. Orrenius, P. Polucci, D. Ballinari, C. Perrera, A. Leone, G.Cervi, A. Galvani, D. Donati, T.O'Brien, P.K. Jackson, A. Isacchi
Abstract 1775
Characterization of New Highly Selective and Potent PARP-1 Inhibitors
A.Montagnoli, G.Papeo, S. Rainoldi, A. Ciavolella, F. Sola, R. Lupi, M. Ciomei, A. Cirla, A. Scolaro, H. Posteri, D. Donati, E. Felder, A. Isacchi, E. Pesenti, A. Galvani
Abstract 3754
Characterization of NMS-P285, a new highly selective and potent BRAF inhibitor
M. Pulici, N. Amboldi, W. Pastori, C. Marchionni, G. Traquandi, S. Cribioli, R. Lupi, M. Modugno, E. Casale, A. Scolaro, E. Felder, D. Donati, A. Isacchi, E. Pesenti, A.Galvani, M. Ciomei - February 4-8
SLAS 2012
San Diego, CA
Web link - February 1-2
World Cancer Metabolism Summit
Washington, D.C.
Web link
Archive 2011
- November 21-23
Computationally Driven Drug Discovery Meeting
L'Aquila, Italy
Web link - November 11-16
EORTC Meeting 2011: Molecular Targets and Cancer Therapeutics
San Francisco, CA
Web link
Abstract
In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori
E. Ardini, M. Menichincheri, P. Banfi, MB. Saccardo, L. Rusconi, N. Avanzi, N. Amboldi, D. Casero, F. Zuccotto, J. Bertrand, M. Fasolini, A. Isacchi, D. Donati, E. Pesenti, A. Galvani
Abstract
NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations
C. Ciomei, I. Fraietta, A. Marsiglio, D. Casero, M. Nesi, D. Donati, A. Isacchi, E. Pesenti, A. Galvani, A. Lombardi Borgia
Abstract
Targeting the Mitotic Checkpoint with NMS-P153 a Novel MPS1 Kinase Inhibitor
R. Colombo, M. Caldarelli, ML. Giorgini, F. Sola, P. Cappella, C. Perrera, N. Avanzi, JA. Bertrand, E. Pesenti, A. Isacchi, D. Donati, A. Galvani
Abstract
Antitumor activity of GBR 500, a monoclonal VLA-2 antibody
S. Hou, E. Pesenti, L. Mancini, H. Mottl - November 6-9
7th NCRI Cancer Conference
Liverpool,UK
Web link - November 5-7
XIII Congresso Nazionale di Oncologia Medica
Bologna, IT
Web link - October 25-28
3rd World ADC Summit
San Francisco, CA
Web link - October 15-18
Translation of the Cancer Genome: Scientific, Clinical, and Operational Challenges
San Francisco, CA
Web link - October 5-8
29° Congresso Nazionale di Citometria
Salerno, IT
Web link
Abstract
IRIS™Dots nanoparticles as a novel tool for flow cytometry analysis and multi cellular culture approach
P. Cappella, A. Giannitti, C. Bertolino, G. Caputo, J. Moll,A.Galvani - September 23-27
The European Multidisciplinary Cancer Congress
Stockholm, SW
Web link - September 21-22
Biacore and MicroCal User's meeting
Assago, IT
Web link
Oral presentation
Isothermal Calometric contributions to drug discovery at Nerviano Medical Sciences
M. Fasolini - September 11-16
XXIV Congresso Nazionale della Società Chimica Italiana
Lecce, IT
Web link
Oral presentation
Synthesis and SAR of New Pyrazolo[4,3-h]quinazoline-3-carboxamide Derivatives as Potent and Selective MPS1 Kinase Inhibitors
M. Caldarelli - August 21-25
ASMC Advances in Synthetic and Medicinal Chemistry
St. Petersburg, Russia
Web link - July 6-8
3rd WIN Symposium in personalized cancer medicine
Paris, FR
Web link
Oral presentation
A successful interaction between Academia, Pharma (Nerviano Medical Sciences) and Oncology network ofLombardy
A. Isacchi, A. Galvani - June 30
Joint Meeting on medicinal chemistry
Catania, Italy
Web link
Oral presentation
Cdc7 kinase inhibitors: a new approach for anticancer therapy
M. Menichincheri - June 20-23
Cancec Proteomics - Systems Biology, Developmental Models & Data Integration
Dublin, IR
Web link - June, 8-9
12th Annual Drug Discovery Leaders Summit
Zurigo, Switzerland
Web link - June 6-8
Next-Gen Kinase Inhibitors
Cambridge (MA)
Web link - June 7-8
6th Annual Cell-Based Assays Meeting
Berlin, Germany
Web link
Oral presentation
Increasing the throughput: Scaling high-content screening to high-throughput screening for lead discovery and optimisation
F. Gasparri - June 6-8
Next-Gen Kinase Inhibitors
Cambridge, MA
Web link - May 17
Tackling attrition in drug discovery & development
Verona, IT
Web link - May 10
2° Luciferase Symposium "What is GLOing on in your cells?"
Milan, Italy
Web link
Oral presentation
Kinase Glo® and ADP GloTM: Universal Bioluminescent Systems to Monitor Protein Kinases Activities
A. Leone - April 13-15
GPCR & Kinase target conference
London, UK
Web link
Oral presentation
Cdc7 kinase: a new target for drug development
A. Montagnoli - April 2-6
AACR
Orlando, US
Web link
Abstract LB-294
GBR 500, a monoclonal VLA-2 antibody inhibits tumor and metastasis growth but not extravasation in a prostate cancer animal model
A. Attinger, S. Hou, E.A. Pesenti, L. Mancini, H. Mottl - March 31- April 1
Risonanza Magnetica in Medicina: dalla ricerca tecnologica avanzata alla pratica clinica
Roma, Italy
Web link
Abstract
Multimodal imaging in an orthotopic mouse model of pancreatic cancer
Russo M, Mancini L, Texido G, Veronelli W, Pesenti E, Degrassi A
Abstract
In vivo imaging of labelled neural stem cells in a mouse model of spinal cord injury
Degrassi A, Russo M, Ottobrini L, Lui R, Merli D, Marfia G, Gorio A, Pesenti E, Lucignani G - March 22-23
10th Annual Targets & Tools: Protein Kinases
Berlin, Germany
Web link
Oral presentation
Selectivity of kinase inhibitors in the context of the emergence of drug resistance
J. Moll - March 7-9
TAT 2011
Paris, FR
Web link - March 7-8
Global Discovery & Development Innovation Forum Summit 2011
London, UK
Web link
Oral presentation
Overcoming drug resistance in oncology therapeutics
J. Moll - February 23-24
6th Annual Biomarkers Congress 2011
Manchester, UK
Web link - February 5-8
Cell Cycle Regulators: Inhibitors and Cancer
Vienna, Austria
Web link
Oral presentation
Destabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cells: focus on MPS1 inhibitorsDestabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cells: focus on MPS1 inhibitors
R. Colombo
Archive 2010
- November 16-19
EORTC-NCI-AACR
Berlin, Germany
Web link
Abstract
Pharmacological characterization of NMS-P506, a novel second generation HSP90 inhibitor
S. Mantegani, N. Amboldi, A. De Ponti, L. Gianellini, M. Guanci, M. Paolucci, D. Donati, E. Pesenti, A. Isacchi
Abstract
NMS-P118, a Parp-1 selective inhibitor with efficacy in DNA repair deficient tumor models
A. Montagnoli, S. Rainoldi, F. Sola, H. Posteri, R. Lupi, E. Pesenti, D. Donati, J. Moll, D. Pezzetta, G. Papeo
Abstract
Activity of the Cdc7 inhibitor NMS-1116354 as single agent and in combination in breast cancer models
A. Montagnoli, D. Ballinari, A. Ciavolella, S. Rainoldi, M. Menichincheri, E. Pesenti, A. Galvani, A. Isacchi, J. Moll
Abstract
Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer
E. Ardini, A. Lombardi Borgia, C. De Ponti, N. Amboldi, D. Ballinari, M.B. Saccardo, P. Magnaghi, E. Pesenti, A. Isacchi, A. Galvani
Abstract
NMS-E628, a potent and orally available small molecule inhibitor of Anaplastic Lymphoma Kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC
E. Ardini, M. Menichincheri, P. Magnaghi, C. De Ponti, N. Amboldi, A. Degrassi, M. Russo, P. Orsini, E. Pesenti, A. Galvani - October 6-8
MASSA
Milano, IT
Web link
Oral presentation
Setup of a Flow Injection Method for the Study of Non-Covalent Interaction on Biopolymers
F. Riccardi Sirtori - September 29-October 2
XXVIII Conferenza Nazionale di Citometria
Urbino, IT
Web link
Oral presentation
Click chemistry" e analoghi della BrdU: nuove strategie nello studio della sintesi del DNA
P. Cappella - September 29-30
Optimizing Early Phase Oncology Studies to Accelerate Proof of Concept
Brussels, Belgium
Web link
Oral presentation
Case Studies from Nerviano Medical Sciences: Planning and Implementing FIH Studies
S. Crippa - 27-28 September 2010
NIH CTEP Meeting
Bethesda, USA
Web link
Oral Presentation
Preclinical characterization of ALK inhibitor NMS-E628 in ALCL and NSCLC tumor models
A. Galvani - September 21-22
Innovation in Phase I clinical development
Munich, Germany
Web link
Oral presentation
Resistance mechanisms of targeted therapies
J. Moll - September 21-22
ESSCA 2010
Valencia, Spain
Web link
Oral presentation
BrdU versus "Click chemistry" : new opportunitis for DNA synthesis in flow and image cytometry
P. Cappella - September 12-16
NMMC 2010 - XX National Meeting on Medicinal Chemistry
Abano Terme, IT
Web link
Oral presentation
Development of pyrazolo-quinazolines as CDK inhibitors: identification of PHA-848125, a potent, orally available compound
MG. Brasca
Abstract
Identification of N-{6,6-DIMETHYL-5-[(1-METHYLPIPERIDIN-4-YL)CARBONYL]-1,4,5,6-TETRAHYDRO PYRROLO[3,4-c]PYRAZOL-3-YL}-3-METHYLBUTANAMIDE, a potent CDK inhibitor suitable for intravenous dosing
P.Orsini - September 5-9
XXIst International Symposium on Medicinal Chemistry
Brussels, Belgium
Web link
Abstract
Cdc7 kinase inhibitors: 2-heteroaryl-3-carboxamido-5-aryl pyrroles as potential anticancer agents
M. Menichincheri - August 22-26
ACS
Boston, US
Web link
Abstract
Benzo[d]imidazole/indole inhibitors of coactivator associated argininemethyltransferase 1 (CARM1)
H. Wan, T. Huynh, S. Pang, J. Geng, T. Bandiera, S. Bindi, P. Vianello, F. Roletto, S. Thieffine, A. Galvani, W. Vaccaro, M. A Poss, G. L Trainor, M. V. Lorenzi, M. Gottardis, L. Jayaraman, A.V. Purandare - July 21
Italian MRI/MRS Users' Meeting
Torino, IT
Web link
Oral presentation
"In vivo" homing of labelled neural stem cells in a mouse model of spinal cord injury
A. Degrassi - July 8-10
Secondo Congresso Nazionale di Bioingegneria
Torino, IT
Web link
Abstract 60
Quantitative evaluation of the Aurora inhibitor effect on gene and protein expression: a mathematical modelling approach
N. Terranova, R. Bosotti, Carpinelli P, G.Galli, M Bertolotti, P. Magni - June, 21-23
Next generation kinase inhibitors - Oncology and Beyond
Cambridge, MA
Web link
Oral presentation
Mitotic spindle kinase inhibitors to target aneuploid cancer cells.
J. Moll
Oral presentation
New trends and opportunities in kinase inhibitors design.
F. Zuccotto - June, 8-9
The 5th annual cell-based assays conference
Cologne
Web link
Oral presentation
Cell-based profiling and screening assays for protein kinases.
F. Gasparri - June 4-8
ASCO
Chicago, US
Web link
Abstract 2087
Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).
A. Benouaich-Amiel, E. Mazza, C. Massard, P. Gaviani, F. Fiorentini, A. Scaburri, M.A. Pacciarini, E. Calvo
Abstract 3063
Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.
R. Bahleda, A. Spreafico, J. C. Soria, C. Moldovan, C. Belli, F. Fiorentini, A. Scaburri, M.A. Pacciarini, B. L'affranchi, M. Reni
Abstract 3065
Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.
S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini, A. Scaburri, M. A. Pacciarini, R. Alzani, L. Gianni
Abstract 3066
Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.
P.J. Rosen, A.W. Tolcher, P. Lee, M. Smitley, M. Fuerst, R. Spinelli, S. Crippa, M.G. Jannuzzo, S. Comis, K. Papadopoulos
Abstract 5014
Phase II study of danusertib in advanced/ metastatic breast and ovarian cancers.
C. Sessa, E. Gallerani, J.P. Delord, P. Schöffski, I. Vergote, V. Trillet-Lenoir, M. Maur, M.G. Jannuzzo, A. Petroccione, G. Locatelli, D. Lorusso - May, 26-27
Targeted Cancer Therapies
London, EN
Web link
Oral presentation
Cancer Cell Specificity for Cell Cycle Inhibitors - a Paradox or an Opportunity?
J. Moll - May, 16-20
28th Camerino-Cyprus-Noordwijkerhout Symposium
Camerino, IT
Web link
Oral presentation
G protein coupled receptors: old landscape with new eyes.
D. Donati - April 17-21
AACR
Washington, US
Web link
Abstract 691
In vitro and in vivo characterization of a selective orally available PARP-1 inhibitor with anti-tumor efficacy in BRCA negative cancer models.
G. Papeo, S. Rainoldi, L.. Gianellini, A. Ciavolella, E. Corti, A. Leone, R. Lupi, F. Sola, F. Caprera, M. Paolucci, R. Perego, C. Albanese, E. Casale, B. Forte, M. Guanci, P. Orsini, H. Posteri, A. Scolaro, F. Riccardi-Sirtori, F. Zuccotto, D. Pezzetta, D. Donati, J. Moll, A. Montagnoli
Abstract 2522
Identification and characterization of new highly selective and potent BRAF inhibitors.
M. Pulici, N. Amboldi, S. Biondaro, F. Caprera, E. Casale, F. Gasparri, A. Leone, R. Lupi, C. Marchionni, M. Modugno, W. Pastori, G. Traquandi, F. Zuccotto, F. Colotta, D. Donati, E. R. Felder, A. Galvani, A. Isacchi, E. Pesenti, M. Ciomei
Oral presentation
NMS-1116354: more than an inhibitor of Cdc7 kinase in S-phase.
F. Colotta - March, 4-6
TAT
Bethesda, US
Web link
Oral presentation
Danusertib, a pan-aurora kinase inhibitor: Clinical review.
B. Laffranchi - February 11-12
Screening Europe
Barcelona, SP
Web link
Oral presentation
MPS-1 kinase inhibition in cancer cells: the fast track to cell death.
J. Moll - February 4-5
Risonanza Magnetica in Medicina
Milano, IT
Web link
Oral presentation
MRI and PET evaluation of disease progression and efficacy of a cell cycle inhibitor on a lung adenocarcinoma transgenic mouse model.
A. Degrassi
Archive 2009
- September 13-17
Eurotox
Dresdn
Web link - May 29-June 2
American Society of Clinical Oncology
Orlando,FL
Web link - April 18-22
Amercan Association for Cancer Research
Denver, Co
Web link - march 16-18
BIO-SPRING
Milan, Italy
Web link - march 15-19
SOT
Baltimore, Maryland
Web link - March 3-4
8th Annual Protein Kinases Congress 2009
Barcelona
Web link - February 23
Drug Screening 2009
Berlin, Germany
Web link - February 23-25
ADMET
Berlin,Germany
Web link - February 13
Application of Bioanalysis in the Clinical-Pharmaceutical sector
Catania, Italy - February 8-11
Chemistry in Cancer Research: A vital parternship in carcer drug discovery and development
New Orleans
Web link - January 25
Keystone Symposium Omics Meet Cell Biology
Breckenridge, Colorado
Web link - Jannuary 19-22
Sitox
Verona
Web link - January 12
Model Based Drug Development
Philadelphia
Archive 2008
- December 6-9
ASH 50th annual Meeting
San Francisco
Web link - December 2nd-3rd
WDD - 7th World Drug Discovery & Development
Prague
Web link - November 12-14
25th LC/MS Montreux Symp of the IAEAC (Int Ass of Environmental Analytical Chem)
Montreux
Web link - September 30 - October 2
CPhI
Frankfurt
Web link - October 21-24
20th EORTC-NCI-AACR Symposium on Molecular Targets& Cancer Therpeutics
Geneva (Switzerland)
Web link - October 14-16
MipTech Conference The Leading European event for Drug Discovery
Basel - October 5-8
Eurotox 2008
Rhodes, Greece
Web link - September 22-25
SPS, Safety Pharm Society
Madison, Wisconsin USA
Web link - September 21-26
ETS: 37th Annual Mtng of the European Teratology Society
Edinburgh
Web link - September 16-18
BIOBUSINESS network 2008
Geneva - September 12-16
ESMO
Stockholm
Web link - August 31 September 4
EFMC-ISCM 2008 XXth Int. Symposium on Medicinal Chemistry
Vienna
Web link - August 17-21
ACS 236th National Meeting
Philadelphia
Web link - June 26
Protein Kinase targets
Boston
Web link - June 22-25
2008 AAPS - National Biotechnology Conference
Toronto
Web link - June 17-20
BIO - San Diego
San Diego
Web link - June 12-13
Isotope Society Meeting
Bad Soden
Web link - June 8-12
PBA 2008
Gdañsk (Polonia)
Web link - May 30- June 3
ASCO
Chicago
Web link - May 29 - June 4
EMBO Meeting - Cellular Signaling & Molecular medicine
Dubrovnik
Web link - May 19-21
4th Annual Biomarker World Congress 2008
Web link - May18-21
10th European ISSX Meeting
Vienna
Web link - May 18-21
10th European ISSX Meeting
Vienna
Web link - May 14-18
The Cell Cycle
Cold Spring Harbour (New York)
Web link - April 12-16
AACR
San Diego
Web link - April 7-9
Bio Europe Spring 2008
Madrid
Web link - August 17-21
ACS 235th National Meeting
New Orleans
Web link - April 6 -10
SBS Meeting
Web link - March 16-20
SOT
Seattle
Web link - March 10-11
Development of safe protein Therapeutics: preclinical, clinical and regulatory issues - EUFEPS
Munich
Web link